INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

Rhea-AI Summary

INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has scheduled its Fourth Quarter 2024 financial results conference call for March 27, 2025, at 4:30 PM EDT. The company will present its financial performance for the quarter ended December 31, 2024, along with a corporate update.

Investors and interested parties can join via phone using the dial-in numbers 1-800-225-9448 or 1-203-518-9708 with Conference ID: INMUNE. A live audio webcast will be available, and a transcript will be provided approximately 24 hours after the call. A replay option will also be accessible.

Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for its quarter ended December 31, 2024, and to provide a corporate update.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator.

Date: March 27, 2025

Time: 4:30 PM Eastern Time

Participant Dial-in: 1-800-225-9448 or 1-203-518-9708

Conference ID: INMUNE

A live audio webcast of the call can be accessed by clicking here or using this link:

https://viavid.webcasts.com/starthere.jsp?ei=1704589&tp_key=4727e947f4

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available by calling 1-844-512-2921 or 1-412-317-6671

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. To learn more, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:

David Moss, CFO
(858) 964-3720
info@inmunebio.com

Investor Contact:

Daniel Carlson, Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com

FAQ

When will INmune Bio (INMB) release its Q4 2024 earnings?

INmune Bio will release its Q4 2024 earnings on March 27, 2025, at 4:30 PM EDT.

How can investors join INmune Bio's Q4 2024 earnings call?

Investors can dial 1-800-225-9448 or 1-203-518-9708 (Conference ID: INMUNE) or access the webcast through the company's provided link.

Will there be a replay available for INMB's Q4 2024 earnings call?

Yes, a replay will be available by calling 1-844-512-2921 or 1-412-317-6671.

When will the transcript of INMB's Q4 2024 earnings call be available?

The transcript will be available approximately 24 hours after the scheduled call.